Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Karolinska Development AB ( (SE:KDEV) ) has issued an update.
Karolinska Development AB has divested its remaining shares in OssDsign, generating a capital injection of approximately SEK 34.5 million. This decision reflects the company’s strategy to strengthen its financial position and prioritize investments with greater potential for value creation and higher returns. The divestment marks the end of Karolinska Development’s direct ownership in OssDsign, although it retains an indirect stake through the KCIF Co-Investment Fund.
More about Karolinska Development AB
Karolinska Development AB is a Nordic life sciences investment company focusing on breakthrough medical innovations in the Nordic region. The company invests in the growth of companies that develop commercial products aimed at improving patients’ lives while ensuring attractive returns for shareholders. It has a portfolio of eleven companies targeting innovative treatments for serious diseases and leverages world-class medical innovations from the Karolinska Institutet and other leading research institutes.
Average Trading Volume: 210,243
Current Market Cap: SEK278.5M
Learn more about KDEV stock on TipRanks’ Stock Analysis page.